- Companies
- Nanjing Medlander Medical
Nanjing Medlander Medical Valuation Multiples
Nanjing Medlander Medical is valued at $395M as of October 2026, a 4.6x revenue multiple. In the last fiscal year, Nanjing Medlander Medical revenue was $65M and Nanjing Medlander Medical EBITDA was $20M.
Nanjing Medlander Medical Overview
About Nanjing Medlander Medical
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
Founded
2013
HQ
Employees
582
Website
Financials (Last FY)
EV
$295M
Valuation Multiples
Start free trialNanjing Medlander Medical Financials
Nanjing Medlander Medical reported last fiscal year revenue of $65M and EBITDA of $20M.
In the same fiscal year, Nanjing Medlander Medical generated $45M in gross profit, $20M in EBITDA, and $15M in net income.
Revenue (LTM)
Nanjing Medlander Medical P&L
In the most recent fiscal year, Nanjing Medlander Medical reported revenue of $65M and EBITDA of $20M.
Nanjing Medlander Medical is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 31%, and net margin of 24%.
Financial data powered by Morningstar, Inc.
Nanjing Medlander Medical Stock Performance
Nanjing Medlander Medical has current market cap of $395M, and enterprise value of $295M.
Market Cap Evolution
Nanjing Medlander Medical's stock price is $3.95.
Nanjing Medlander Medical share price decreased by 10.3% in the last 30 days, and by 32.2% in the last year.
Nanjing Medlander Medical has an EPS (earnings per share) of $0.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $295M | $395M | -1.1% | -10.3% | -8.4% | -32.2% | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNanjing Medlander Medical Valuation Multiples
Nanjing Medlander Medical trades at 4.6x EV/Revenue multiple, and 14.5x EV/EBITDA.
EV / Revenue (LTM)
Nanjing Medlander Medical Financial Valuation Multiples
As of October 23, 2026, Nanjing Medlander Medical has market cap of $395M and EV of $295M.
Nanjing Medlander Medical has a P/E ratio of 25.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nanjing Medlander Medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Nanjing Medlander Medical Margins & Growth Rates
Nanjing Medlander Medical grew revenue by 22% and EBITDA by 60% in the last fiscal year.
In the most recent fiscal year, Nanjing Medlander Medical reported gross margin of 70%, EBITDA margin of 31%, and net margin of 24%.
Nanjing Medlander Medical Margins
Nanjing Medlander Medical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Nanjing Medlander Medical Operational KPIs
Nanjing Medlander Medical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Nanjing Medlander Medical's Rule of 40 is 63% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanjing Medlander Medical's Rule of X is 96% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Nanjing Medlander Medical Competitors
Nanjing Medlander Medical competitors include OrbusNeich Medical Group, Carlsmed, Claritev, Senseonics Holdings, Orthofix Medical, Sofwave Medical, CellaVision, Shoulder Innovations, VieMed and Carvolix.
Most Nanjing Medlander Medical public comparables operate across Medical Devices, Healthcare Software, BioTech, B2B SaaS, Vertical SaaS, HealthTech and FemTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $180M | $45M | 1.1x | - | 4.5x | - | |||
| $51M | ($31M) | 6.5x | 4.6x | (10.8x) | (9.4x) | |||
| $965M | $466M | 5.3x | 5.1x | 10.9x | 8.3x | |||
| $35M | ($67M) | 8.8x | 5.3x | (4.6x) | - | |||
| $822M | $4M | 0.7x | 0.6x | 135.2x | 5.8x | |||
| $88M | $7M | 4.4x | - | 55.3x | - | |||
| $77M | $24M | 5.2x | 5.0x | 16.9x | 16.6x | |||
| $47M | ($37M) | 6.9x | 5.1x | (8.8x) | (10.0x) | |||
This data is available for Pro users. Sign up to see all Nanjing Medlander Medical competitors and their valuation data. Start Free Trial | ||||||||
Nanjing Medlander Medical VC Funding History
Before going public, Nanjing Medlander Medical raised $2M in total equity funding, across 2 rounds.
Nanjing Medlander Medical Funding Rounds
Investments by Nanjing Medlander Medical
Nanjing Medlander Medical has invested in 1 company to date.
Latest investment by Nanjing Medlander Medical was on June 4th 2026. Nanjing Medlander Medical invested in Zhimei Keji in their $30M Undisclosed stage round (EV/Revenue multiple available to Pro users).
Latest Investments by Nanjing Medlander Medical
| Description | Zhimei Keji is an e-commerce provider specializing in beauty products such as trendy makeup, facial skincare, makeup tools, bundled sets, body care items, beauty equipment, perfumes, and cleansing products. The company operates via gimay.net to serve consumer markets. |
| HQ Country | |
| HQ City | Shantou |
| Deal Date | 4 Jun 2026 |
| Round | Undisclosed stage |
| Raised | $30M |
| Investors | Nanjing Medlander Medical; Beijing Guoshi Zhida Private Equity Fund Management |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Nanjing Medlander Medical investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nanjing Medlander Medical
| When was Nanjing Medlander Medical founded? | Nanjing Medlander Medical was founded in 2013. |
| Where is Nanjing Medlander Medical headquartered? | Nanjing Medlander Medical is headquartered in China. |
| How many employees does Nanjing Medlander Medical have? | As of today, Nanjing Medlander Medical has over 582 employees. |
| Is Nanjing Medlander Medical publicly listed? | Yes, Nanjing Medlander Medical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Nanjing Medlander Medical? | Nanjing Medlander Medical trades under 688273 ticker. |
| When did Nanjing Medlander Medical go public? | Nanjing Medlander Medical went public in 2022. |
| Who are competitors of Nanjing Medlander Medical? | Nanjing Medlander Medical main competitors include OrbusNeich Medical Group, Carlsmed, Claritev, Senseonics Holdings, Orthofix Medical, Sofwave Medical, CellaVision, Shoulder Innovations, VieMed, Carvolix. |
| What is the current market cap of Nanjing Medlander Medical? | Nanjing Medlander Medical's current market cap is $395M. |
| What is the current revenue of Nanjing Medlander Medical? | Nanjing Medlander Medical's last fiscal year revenue is $65M. |
| What is the current revenue growth of Nanjing Medlander Medical? | Nanjing Medlander Medical revenue growth (vs. last FY) is 22%. |
| What is the current EV/Revenue multiple of Nanjing Medlander Medical? | Current revenue multiple of Nanjing Medlander Medical is 4.6x. |
| Is Nanjing Medlander Medical profitable? | No, Nanjing Medlander Medical is not profitable. |
| How many companies Nanjing Medlander Medical has acquired to date? | Nanjing Medlander Medical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Nanjing Medlander Medical has invested to date? | As of October 2026, Nanjing Medlander Medical has invested in 1 company. |
| What was the last Nanjing Medlander Medical investment? | On 4th June 2026 Nanjing Medlander Medical invested in Zhimei Keji, participating in a $30M Undisclosed stage round, alongside Beijing Guoshi Zhida Private Equity Fund Management. |
| In what companies Nanjing Medlander Medical invested in? | Nanjing Medlander Medical invested in Zhimei Keji. |
See public comps similar to Nanjing Medlander Medical
Lists including Nanjing Medlander Medical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




